Anteris Technologies Global Corp. (AVR) is a pre-commercial structural heart device company. Under the liquidation lens at March 31, 2026, the recovery posture is materially positive relative to prior periods, driven almost entirely by the January 2026 capital raises. The company completed a $230M public offering and a $90M Medtronic private placement simultaneously, generating net cash proceeds of approximately $300M after $8.2M of issuance costs. Total cash, cash equivalents, and restricted cash stands at $283.2M (period-end), up from $12.6M at December 31, 2025 — a $270.6M increase in the quarter. Cash equivalents of $251M are held in money market deposits, treasury bills, and term deposits, all of which liquidate at 100% under standard recovery assumptions. This cash position is the dominant liquidation asset. Non-cash assets are immaterial: PP&E net $5.2M (50-70% recovery = $2.6-3.6M), operating ROU asset $2.8M (zero recovery), intangibles $0.1M (zero recovery), inventory $0.1M (60% = ~$0.07M), and receivables $0.2M (90-95% recovery). Total estimated liquidation asset recovery approximates $285-287M against total liabilities of $16.3M at face value. The liability stack is thin: current liabilities of $13.7M (accounts payable $3.8M, accrued liabilities $8.6M, current lease obligations $0.6M, current debt/finance lease $0.7M) and non-current liabilities of $2.6M (operating lease $2.4M, other $0.2M, LT finance lease $18K). Net estimated recovery to equity holders approximates $269-271M against reported book equity of $278M. The MFFAIS CLV/LLV/OLV figures of approximately $550M significantly exceed this bottom-up estimate; the gap reflects going-concern value attributed to the DurAVR THV pipeline, which liquidation analysis zeros out entirely. The company carries a $393.6M accumulated deficit and burned $28.7M cash in operations in Q1 2026 (vs. $21.5M in Q1 2025, a 33% acceleration), reflecting PARADIGM Trial ramp-up costs. Subsequent to period end, the company entered a new Brooklyn Park, MN lease (commencing September 2026) with a $3.5M standby letter of credit; this lease is unrecognized at March 31, 2026 but will add to the operating lease liability stack in Q3 2026 and reduce restricted cash by $3.5M. The v2vmedtech VIE was terminated post-period with a $0.4M break fee; consolidated VIE assets were $33K and liabilities $81K at period end — immaterial. Filing discloses $3.5M undiscounted lease commitments ($3.0M discounted) for existing properties. Ongoing material weakness in internal controls over financial reporting (unremediated through Q1 2026) is an audit risk flag but does not independently affect liquidation value. The 4C tissue supply agreement expires June 1, 2026 with no early termination penalty; revenue from this line ($0.5M quarterly) will cease.
▼ Community Notes